Overcoming ibrutinib resistance in mantle cell lymphoma

克服套细胞淋巴瘤中的依鲁替尼耐药性

基本信息

项目摘要

Project Abstract Ibrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK) and similar inhibitors of B-cell receptor (BCR)- associated kinases are shifting the therapeutic landscape in B-cell neoplasia. However, the development of resistance in patients treated with these agents is associated with rapidly progressive disease and death. Mutations in BTK and its downstream target phospholipase Cγ2 have been implicated in resistance to ibrutinib in chronic lymphocytic leukemia (CLL). While such mutations are found in a subset of mantle cell lymphoma (MCL) patients, they do not account for all patterns of ibrutinib resistance. Recent studies have implicated nuclear factor-κB (NFκB) as a potential critical component of resistance in MCL. The pathogenic contribution of NFκB is supported by identification of a) activation of NFκB signaling pathways within the lymph node microenvironment; b) constitutive NFκB activity resulting from recurrent mutations in TRAF2, BIRC3 and RELA; and c) mutations in genes affecting NFκB signaling in primary ibrutinib-refractory MCL samples. Thus, tumor-intrinsic and microenvironment-driven NFκB activation may underlie a significant fraction of ibrutinib failures. However, the role of NFκB has not been studied prospectively in this setting. We hypothesize that NFκB and its transcriptional targets are upregulated in patients who exhibit resistance to ibrutinib. Under Aim 1, we will conduct a prospective study to determine functional significance of NFκB activation in ibrutinib resistance in MCL. We will comprehensively evaluate NFκB signaling in primary MCL cells obtained from bone marrow and/or lymph nodes prior to the start of ibrutinib, on therapy and at relapse. Given the emerging importance of NFκB in MCL, an optimal therapeutic approach would incorporate targeting NFκB activation. In evaluating the NFκB pathway as a therapeutic target, we discovered that it can be neutralized via blockade of upstream regulators in the ubiquitin-proteasome system (UPS). Our data indicate that NFκB activity may be blocked by targeting NEDD8-activating enzyme (NAE; a ubiquitin-like modifier) in neoplastic B-cells, resulting in cell apoptosis. We hypothesize that therapeutic disruption of NFκB by blocking the NAE will overcome ibrutinib resistance in MCL. Thus, Aim 2 will evaluate therapeutic targeting of the E1 ligase, NAE, in ibrutinib- resistant MCL. We will elucidate functional effects of inhibiting NAE on NFκB signaling, cell apoptosis in MCL cell lines and primary ibrutinib-resistant cells in vitro and in a murine MCL xenograft model. Finally, Aim 3 will assess the NAE inhibition-mediated deregulation of NFκB in neoplastic B cells and T cells obtained from patients who receive treatment with pevonedistat and ibrutinib on a clinical trial. Our study will test novel approaches to overcome ibrutinib resistance through NFκB inactivation, and thus significantly impact MCL therapeutics.
项目摘要 伊布鲁替尼,布鲁顿酪氨酸激酶(BTK)和类似的B细胞受体(BCR)抑制剂的共价抑制剂- 相关的激酶正在改变B细胞肿瘤的治疗格局。然而,中国的发展 接受这些药物治疗的患者的耐药性与迅速进展的疾病和死亡有关。 Btk及其下游靶基因磷脂酶Cγ2的突变与伊布鲁替尼的耐药性有关 慢性淋巴细胞白血病(CLL)。而这种突变是在套细胞淋巴瘤的一个亚群中发现的 (MCL)患者,他们并不能解释ibrutinib耐药的所有模式。最近的研究表明, 核因子-κB(核因子-κB)作为MCL耐药的潜在关键成分。黄连的致病作用 核因子κB是由a)激活淋巴结内的核因子κB信号通路支持的 微环境;b)TRAF2,BIRC3和TRAF2,BIRC3,TRAF2,BIRC3和TRAF2,BIRC3,TRAF2,BIRC3,TRAF2,BIRC3和κ C)在对伊布鲁替尼耐药的原发微淋巴细胞系样本中,影响核因子κB信号转导的基因突变。因此, 肿瘤内在和微环境驱动的NFκB激活可能是伊布鲁替尼的重要组成部分 失败。然而,在这一背景下,还没有前瞻性地研究NFκB的作用。我们假设 在对伊布鲁替尼表现出耐药的患者中,NFκB及其转录靶点上调。在目标1下, 我们将进行一项前瞻性研究,以确定伊布鲁替尼中核因子κB激活的功能意义 MCL中的抗性。我们将全面评估从骨获得的原代MCL细胞中的NFκB信号 伊布鲁替尼开始治疗前、治疗时和复发时的骨髓和/或淋巴转移。鉴于新兴的 核因子κB在微淋巴细胞性淋巴瘤中的重要性,最佳的治疗方法应包括靶向核因子κB的激活。在……里面 评价作为治疗靶点的核因子κB通路,我们发现它可以通过阻断 泛素-蛋白酶体系统(UPS)的上游调节因子。我们的数据表明,核因子κB的活性可能是 通过靶向肿瘤B细胞中的NEDD8激活酶(NAE;一种泛素样修饰物)而被阻断,结果 在细胞凋亡中。我们推测,通过阻断NAE对核因子κB的治疗干扰将克服 MCL对伊布鲁替尼耐药。因此,AIM 2将评估伊布鲁替尼中E1连接酶NAE的治疗靶向性。 抗性MCL。我们将阐明抑制NAE在MCL中对NFκB信号转导、细胞凋亡的作用 体外和小鼠MCL异种移植模型中的伊布鲁替尼耐药细胞系和原代耐药细胞。最后,《目标3》将 评估NAE抑制介导的肿瘤B细胞和T细胞中NFκB的去调节作用 在临床试验中接受培诺地塞米松和伊布鲁替尼治疗的患者。我们的研究将测试小说 通过核因子κB失活克服伊布鲁替尼耐药性的方法,从而显著影响MCL 治疗学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexey V. Danilov其他文献

Pharmacodynamic Analysis of Mcl-1 and RNA Pol IIsupSer2/sup Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib
维奈托克联合沃罗诺克拉治疗复发性或难治性急性髓系白血病患者的原始细胞中 Mcl-1 和 RNA 聚合酶 II 丝氨酸 2 磷酸化的药效学分析
  • DOI:
    10.1182/blood-2024-203689
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Nathalie Javidi-Sharifi;Jeremy Zhang;Sandra Wiley;Richard G Ghalie;Alexey V. Danilov;Matthew S. Davids
  • 通讯作者:
    Matthew S. Davids
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
格罗菲妥单抗可刺激中枢神经系统肿瘤的免疫细胞浸润,并在继发性中枢神经系统淋巴瘤中诱导临床缓解 。
  • DOI:
    10.1182/blood.2024024168
  • 发表时间:
    2024-07-25
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    James K. Godfrey;Lei Gao;Geoffrey Shouse;Joo Y. Song;Stacy Pak;Brian Lee;Bihong T. Chen;Avyakta Kallam;John H. Baird;Guido Marcucci;Lucy Ghoda;Stephanie Vauleon;Alexey V. Danilov;Alex F. Herrera;Larry W. Kwak;Lihua E. Budde
  • 通讯作者:
    Lihua E. Budde
Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia
  • DOI:
    10.1182/blood-2024-204184
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Tiana Huynh;Sonia Rodriguez-Rodriguez;Carly Roleder;Sarah Whelan;May Tan;Ernestine Lee;Paul Munson;Alexey V. Danilov
  • 通讯作者:
    Alexey V. Danilov
Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and <em>TP53</em> Mutation Status
  • DOI:
    10.1182/blood-2024-204269
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Tycel J. Phillips;Alexey V. Danilov;Jia Ruan;Krish Patel;Anita Kumar;Yucai Wang;Gregory A. Maglinte;Erlene Seymour;Manali Kamdar
  • 通讯作者:
    Manali Kamdar
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
  • DOI:
    10.1007/s11899-021-00605-9
  • 发表时间:
    2021-01-28
  • 期刊:
  • 影响因子:
    3.300
  • 作者:
    Edward Nabrinsky;Alexey V. Danilov;Paul B. Koller
  • 通讯作者:
    Paul B. Koller

Alexey V. Danilov的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexey V. Danilov', 18)}}的其他基金

Overcoming ibrutinib resistance in mantle cell lymphoma
克服套细胞淋巴瘤中的依鲁替尼耐药性
  • 批准号:
    10320471
  • 财政年份:
    2021
  • 资助金额:
    $ 44.13万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 44.13万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了